Skip to main content

Table 2 Number of patients with drug-related adverse events

From: A phase I dose-escalation study of a biosimilar trastuzumab in Chinese metastasis breast cancer patients

 

Total (n = 27)

100 mg (n = 9)

250 mg (n = 9)

500 mg (n = 9)

Rang 1.35–1.89 mg/kg

Rang 3.65–6.25 mg/kg

Rang 6.41–11.11 mg/kg

Grade 1/2 No. (%)

Grade 3/4 No. (%)

Grade 1/2 No. (%)

Grade 3/4 No. (%)

Grade 1/2 No. (%)

Grade 3/4 No. (%)

Grade 1/2 No. (%)

Grade 3/4 No. (%)

Fever

16 (59.3)

0

5 (55.6)

0

3 (33.3)

0

8 (88.9)

0

Transit increased ALT/AST

6 (22.2)

0

1 (11.1)

0

3 (33.3)

0

2 (22.2)

0

Chills

5 (18.5)

0

2 (22.2)

0

2 (22.2)

0

1 (11.1)

0

Arrhythmia

5 (18.5)

1 (3.7)

2 (22.2)

0

2 (22.2)

1 (11.1)

0

0

Fatigue

4 (14.8)

0

1 (11.1)

0

2 (22.2)

0

1 (11.1)

0

Dyspnea

4 (14.8)

0

1 (11.1)

0

3 (33.3)

0

0

0

Arthralgia

4 (14.8)

0

2 (22.2)

0

2 (22.2)

0

0

0

Nausea/vomiting

3 (11.1)

0

1 (11.1)

0

2 (22.2)

0

0

0

Palpitation

3 (11.1)

0

1 (11.1)

0

2 (22.2)

0

0

0

Headache

2 (7.4)

0

2 (22.2)

0

0

0

0

0

Dry mouth

2 (7.4)

0

1 (11.1)

0

0

0

1 (11.1)

0

Rash

2 (7.4)

0

1 (11.1)

0

1 (11.1)

0

0

0